Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2021-08-06 00:00:00 ET · period of report 2021-08-05 · accession 0001708138-21-000044 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-08-06 | 2021-08-05 | REGN | YANCOPOULOS GEORGE | Pres, Chief Scientific, Dir | S - Sale | $600.06 | -50.0K | 937.5K | -5% | -$30.00M | |
| MI | 2021-08-06 | 2021-06-24 | REGN | YANCOPOULOS GEORGE | Pres, Chief Scientific, Dir | G - Gift | $0.00 | 0 | 213.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-05 | S | D | 50,000 | $600.06 | 937,483 | D By Trust for Chldn. | — | — | (F2) Represents volume-weighted average price of sales of 50,000 shares of Company stock on August 5, 2021 at prices ranging from $600.00 to $600.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price. (F3) As investment trustee of trusts for the benefit of the reporting person's children. |
| 2 | Common | Common Stock | 2021-06-24 | G | D | 211,585 | $0.00 | 0 | I | — | — | |
| 3 | Common | Common Stock | 2021-06-24 | G | A | 211,585 | $0.00 | 213,693 | I by 2019 GRAT | — | — |